Health Care • Biotechnology: Pharmaceutical Preparations
$1.01 ▼ -0.05
(-4.72%)
MKT CAP: $10.9M • VOL: 27.9K
52W L $1 52W H $5
ROARABLE / RQD
E • 32/100
PIOTROSKI
3 / 9
LSTA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $170.0K | $1.0M | $0 |
| YoY Revenue Growth % | -83.0% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.2M | -$22.4M | -$25.7M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$17.0M | -$20.0M | -$21.0M |
| EBITDA (Normalized) | -$18.2M | -$22.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.9M | -$19.4M | -$20.0M |
| Capital Expenditures (CapEx) | $28.0K | $0 | — |
| Free Cash Flow (FCF) | -$16.0M | -$19.4M | -$20.0M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $16.0M | $16.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $14.9M | $29.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LSTA.